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Abstract
Aim/Hypothesis: The adult mammalian pancreas has limited ability to regenerate in order to restore adequate insulin
production from multipotent progenitors, the identity and function of which remain poorly understood. Here we test
whether the TNF family member TWEAK (TNF-like weak inducer of apoptosis) promotes b-cell neogenesis from proliferating
pancreatic ductal epithelium in adult mice.
Methods: C57Bl/6J mice were treated with Fc-TWEAK and pancreas harvested at different time points for analysis by
histology and immunohistochemistry. For lineage tracing, 4 week old double transgenic mice CAII-CreERTM: R26R-eYFP
were implanted with tamoxifen pellet, injected with Fc-TWEAK or control Ig twice weekly and analyzed at day 18 for TWEAK-
induced duct cell progeny by costaining for insulin and YFP. The effect of TWEAK on pancreatic regeneration was
determined by pancytokeratin immunostaining of paraffin embedded sections from wildtype and TWEAK receptor (Fn14)
deficient mice after Px.
Results: TWEAK stimulates proliferation of ductal epithelial cells through its receptor Fn14, while it has no mitogenic effect
on pancreatic a- or b-cells or acinar cells. Importantly, TWEAK induces transient expression of endogenous Ngn3, a master
regulator of endocrine cell development, and induces focal ductal structures with characteristics of regeneration foci. In
addition, we identify by lineage tracing TWEAK-induced pancreatic b-cells derived from pancreatic duct epithelial cells.
Conversely, we show that Fn14 deficiency delays formation of regenerating foci after Px and limits their expansion.
Conclusions/Interpretation: We conclude that TWEAK is a novel factor mediating pancreatic b-cell neogenesis from ductal
epithelium in normal adult mice.
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Introduction
Diabetes mellitusis manifested as hyperglycemia resulting from
inadequate production of insulin by pancreatic b-cells. The ability
of b-cells to expand or regenerate to restore adequate insulin
production is limited, especially in adults. Attempts to increase b-
cell mass through de novo pancreas regeneration or the expansion
and differentiation of precursors in vitro for cell transplant therapy
have been reported [1,2], with limited success due to lack of
understanding of the identity of b-cell progenitors and mecha-
nisms regulating their fate in adults.
Numerous studies have determined that adult pancreas retains
the intrinsic ability to make new insulin-producing b-cells,
suggesting that facultative pancreatic progenitors exist within
various cell types [3]. The conversion of mature a-cells to b-cells
after extreme b-cell loss [4] and direct trans-differentiation from
pancreatic exocrine cells to b-like cells after ectopic expression of
Ngn3, Pdx1 and Mafa [5] have been reported. Others reported that
adult ductal epithelial cells can give rise to insulin-producing b-
cells in rodents [6,7,8], recapitulating the role of ductal epithelium
in embryonic development. After partial duct ligation (PDL),
Ngn3-positive precursors in or near the ductal epithelium were
found, suggesting activation of endocrine progenitors [9]. Ductal
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epithelium was definitively identified as the precursor for new
endocrine cells and acinar cells both in neonates and after PDL in
adults using the duct-specific carbonic anhydrase II (CAII)
promoter to trace their fate [10]. However, in other lineage
studies using Hnf1b or Sox 9 promoters, duct-derived endocrine
cells were only observed during embryonic development [11,12].
Further investigation is warranted to elucidate pathways promot-
ing pancreatic b-cell regeneration in adults.
One such pathway may be tumor necrosis factor-like weak
inducer of apoptosis (TWEAK), a unique TNF family cytokine
that can regulate cell survival, growth, and differentiation, as well
as inflammation and angiogenesis, through its cognate receptor
FGF-inducible molecule 14 (Fn14) [13,14]. Fn14 is expressed by
non-hematopoietic cell types at relatively low levels in healthy
tissues and dramatically upregulated locally within injured and
diseased tissues [15]. Notably, substantial evidence has emerged
that TWEAK can regulate progenitors expressing Fn14, including
hepatic oval cells [16], skeletal muscle satellite cells and other
mesenchymal lineage cell types.
Previously, we found that TWEAK expands liver progenitor
cells as evidenced by hyperplasia of duct-like structures in liver of
TWEAK-overexpressing mice [16]. Given the close developmen-
tal relationship between liver and pancreas, both arising from
embryonic foregut endoderm [17], we hypothesize that TWEAK
may exert similar effects on pancreatic ductal epithelium with
progenitor potential.
Materials and Methods
Ethics Statement
All studies were carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee (IACUC) of Biogen Idec and Joslin Diabetes Center.
All surgery was performed under anesthesia by i.p. injected
ketamine/xylazine mixture (ketamine at 200 mg/kg b.w. and
xylazine at 10 mg/kg b.w.), and all efforts were made to minimize
suffering.
Animals and Fc-TWEAK generation
C57Bl/6J and R26R-eYFP transgenic (Tg) reporter mice
(Jackson Laboratory, Bar Harbor, ME); Fn14 knockout (KO)
[18] and CAII-CreERTM Tg mice [10] both on C57Bl/6
background were described previously. 8-week-old C57Bl/6
females, at least 4 per group, were injected intraperitoneally
(i.p.) or subcutaneously (s.c.) with 200 mg mouse Fc-TWEAK, a
fusion protein with the murine IgG2a Fc region [19] or mouse
isotype control P1.17 once or twice weekly and then sacrificed at
different time points. Aglycosylated Fc-TWEAK, agly-Fc-
TWEAK, was constructed with the N297Q muIgG1 Fc sequence,
thereby creating an Fc-effector function-deficient protein. For
lineage tracing experiments, CAII-CreERTM Tg mice [10] were
mated with R26R-eYFP mice. Four week old double Tg (bigenic)
were implanted with 3-week slow-release (1–2 mg/day) tamoxifen
(TM) pellet (Innovative Research of America, Sarasota, Florida)
followed by a 1 week washout period, and then injected with
200 mg Fc-TWEAK or control Ig twice weekly and sacrificed at
day 18 after treatment; bigenic mice without TM, Fc-TWEAK or
control Ig treatment were controls. Labeling efficiency is 30–40%
[10].
Tissue preparation and immunohistochemistry
Formalin-fixed human pancreas sections were from quality
control blocks of cadaveric organs donated for islet isolation. Their
use as exempt anonymous tissue had Joslin IRB approval. Fn14
immunostaining was as described [20].
Primary antibodies were: rabbit anti-pan-cytokeratin (CK)
(1:100), guinea pig anti-insulin (1:150), rabbit anti-glucagon
(1:150), and rabbit anti-CD3 (1:250) (Dako USA, Carpinteria,
CA); rabbit anti-Ki-67 (1:100, Vector Laboratories, Burlingame,
CA), rat anti-F4/80 (1:50, AbD Serotec, Raleigh, NC), humanized
anti-Fn14 (P4A8 mAb, 2ug/ml [21], mouse anti-Ngn3 (1:2000,
Developmental Studies Hybridoma Bank, University of Iowa)
guinea pig anti-human insulin (1:200 Millipore, Billerica, MA) and
rabbit anti-GFP (1:4000, MBL International, Woburn, MA).
Biotin-conjugated secondary antibodies were from Vector Labo-
ratories. Antigen retrieval for Fn14 was performed with FICIN
(Invitrogen, San Diego, CA) at 37 uC for 5 min, while for all others
boiling in 0.1 M citrate buffer (pH6) followed by treatment with
dual endogenous enzyme block (Dako). Primary antibodies, except
Ngn3 and GFP, were incubated at room temperature for 1 hr.;
Ngn3 and GFP were incubated overnight at 4uC and amplified
using the tyramide system (Perkin Elmer, Waltham, MA). Anti-
GFP to visualize YFP was pre-incubated overnight with poly-L-
lysine (Sigma-Aldrich, St. Louis, MO) to remove non-specific
staining due to charge [22]. TUNEL staining was performed with
APOPTAG Peroxidase in situ Apoptosis Detection Kit (Chemicon,
Temecula, CA).
Partial pancreatectomy (Px)
Px was performed on C57Bl/6J mice as described for rats [6]
with minor modification. CK-immunostained paraffin sections
(two sections $200 mm apart per animal, 5–9 animals per
phenotype) were examined. Regenerating foci were defined by
their mesenchymal borders, with foci area determined by
ImageScope (Aperio Technologies, Inc., Vista, CA), foci number
determined by manual counting of all foci in the full pancreatic
section, and foci stage defined as previously reported [8].
Image analysis
For quantification of ductal proliferation, the number of Ki-67+
duct or duct adjacent cells and total duct cells were counted on one
full footprint pancreatic section from at least 4 mice per time point
and treatment. At least 300 total duct cells were counted. Cell
types were defined by location and morphology: counted duct cells
were the simple cuboidal cells of the interlobar and intralobar
ducts, while ductal adjacent cells were single cells outside the duct
epithelium but within the ductal stroma; small terminal ductules
(squamous cells) were not included.
Quantification of Ngn3+ cells was performed on two full
footprint pancreatic sections ($200 mm apart) from each animal (4
animals per treatment); for each individual the average of the two
sections was used. The total Ngn3+ cell number per section was
manually counted and total pancreatic cell number per section
counted by ImageScope, and these values were used to calculate
the frequency of Ngn3+ cells.
For quantification of labeled cells in the lineage tracing
experiment, one full footprint pancreatic section of each animal
was scanned with manual counting at 106 for hormone staining
and again for YFP staining. For YFP+ cells, higher magnification
was used to check for co-expression. Hormone positive cells were
categorized as islets (defined as more than 8 cells in cross section)
and aggregates (defined as 8 cells or less in cross section).
Beta Cell Neogenesis in Adult Mice
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Fn14 mRNA expression
Mouse duct cells were isolated from islet-depleted tissue after
collagenase digestion using immunomagnetic separation and anti-
CD44 antibody. RNA from 3 independent samples (each 5–15
mice) was examined by qRT-PCR for Fn14 expression as
described [16] with GAPDH used as internal control.
Statistical analysis
Data are expressed as mean 6 SEM and analyzed by 2-way
ANOVA, with p,0.05 considered significant.
Results
TWEAK promotes proliferation of ductal cells in normal
adult mouse pancreas through its receptor Fn14
Immunostaining of human pancreas for Fn14 showed varying
degrees of pancreatic duct epithelial staining in 3 of 4 human
pancreas from organ donors without pre-existing pancreatic
conditions. The strongest staining was observed in a young, obese
donor with body mass index of 35 (Figure 1A–1B), whereas faint
staining of ducts is shown in a 57-year-old donor (Figure 1C–1D).
Donors also showed positive islet staining. Fn14 expression in the
normal adult mouse pancreas was difficult to detect by immuno-
staining (data not shown) but was highly expressed by normal
pancreatic duct cells at mRNA level (n = 3; values normalized to
GAPDH were 0.014, 0.016, and 0.013, values comparable to
positive control mouse lupus kidney samples); it is possible that
Fn14 expression was upregulated during the isolation process.
We investigated the effect of TWEAK overexpression on
pancreatic ductal cells by Fc-TWEAK injection in normal adult
mice. Increased numbers of Ki-67+ pancreatic duct epithelial cells
and adjacent cells were observed three days after a single injection
(acute treatment) of Fc-TWEAK compared to control Ig (Figure 2A–
2B). Co-staining for Ki-67 and pan-cytokeratin (CK), a duct
epithelial cell marker (Figure 2C–2D) confirmed the ductal
identity of the proliferating cells. We determined the kinetics of
the mitogenic effect of TWEAK in mice treated twice weekly for
two weeks (chronic treatment). Duct cell proliferation was detected as
early as day 1 after exposure and peaked between days 4–10,
although significant proliferation was still detected at day 18
(Figure 2E). Proliferation of duct adjacent cells was somewhat
later, with a significant increase first apparent at day 3 after Fc-
TWEAK treatment, and sustained relatively longer (Figure 2F).
We did not observe any mitogenic effect of TWEAK on the acinar
cells or islet cells at any of these time points. The kinetics of
proliferation after acute Fc-TWEAK followed a similar but less
prolonged pattern as compared to chronic treatment (Figure S1A–
S1B).
Fc-TWEAK induced robust proliferation of duct and duct
adjacent cells in WT but not Fn14 KO mice (Figure 2G–2H),
clearly indicating that the mitogenic effect of TWEAK on duct
cells is dependent upon Fn14. These data suggest that TWEAK
acts directly on Fn14 expressed by pancreatic duct epithelium to
induce proliferation.
TWEAK has proapoptotic and proinflammatory effects in some
contexts [23,24], which raised the possibility that the increased
ductal proliferation might be a secondary effect. To rule out these
possibilities, apoptosis and immune cell infiltration were assessed.
Little TUNEL, CD3 or F4/80 positive staining was seen in the
pancreas of animals treated with control Ig, indicating that few
apoptotic cells, T cells or macrophages are normally present.
Similarly, at all time points studied (day 1, 3, 4, 5, 10 and 18),
there were no changes in TUNEL signal (represented in
Figure S2), and no generalized changes in CD3 or F4/80
expression (Figure S3) after twice weekly Fc-TWEAK as com-
pared to control Ig-treatment. These data indicate that the
increased proliferation of duct and duct adjacent cell induced by
TWEAK was not due to increased cell turnover or generalized
tissue inflammation.
To rule out the possible involvement of Fc-effector functions, we
treated mice twice weekly with agly-Fc-TWEAK, and examined
cell proliferation at day 5 after treatment (Figure S4A–4B). Similar
duct cell proliferation was observed after agly-Fc-TWEAK and Fc-
TWEAK treatment, therefore Fc-effector function is not required.
We also treated mice by subcutaneous instead of intraperitoneal
injection to rule out an effect specific to route of delivery
(Figure S4C–4D).
TWEAK induces endogenous Ngn3+ cells in normal adult
mouse pancreas
Fc-TWEAK robustly induced proliferation of duct cells, so we
investigated its effect on induction of the endocrine progenitor
marker Ngn3 [25]. No Ngn3 expression was detected in pancreas
from control Ig-treated mice. However, at day 4 or 5 after twice
weekly Fc-TWEAK treatment (Figure 3A–C), Ngn3 expression
was mostly detected in small ducts (CK+), centroacinar cells and
duct adjacent cells (Ngn3+ CK2) still in contact with CK+ duct
cells; Ngn3+ cells did not express any islet hormones (data not
shown). These Ngn3+ cells were not distributed evenly over the
whole section but tended to form clusters as shown in Figure 3.
Ngn3 was only detected at day 4 or 5 and numbered only a few
per ten thousand adult pancreatic cells (Figure 3D), which is
consistent with transient expression of Ngn3 shown in embryonic
development [26,27,28].
Figure 1. Fn14 expression by human pancreatic ductal
epithelium. Variable amounts of Fn14 were seen in human pancreas
with fairly strong intensity seen in tissue from a 16-year-old female
donor (A) anti-Fn14 or (B) isotype control, and faint staining in a 57-
year-old donor (C) anti-Fn14 and (D) isotype control. Specific staining
was seen in islets as well as ducts. The islets were labeled as ‘‘i’’. Scale
bar = 50 mm.
doi:10.1371/journal.pone.0072132.g001
Beta Cell Neogenesis in Adult Mice
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Figure 2. TWEAK treatment promotes proliferation of pancreatic duct and duct adjacent cells through its receptor Fn14. Pancreatic
tissue of normal adult mice stained for Ki-67 (black) on day 3 after injection of (A) control Ig or (B) Fc-TWEAK, and costained with Ki-67 (red) and
ductal epithelial marker CK (CK) (green) on day 4 after (C) control Ig or (D) Fc-TWEAK acute treatment. Scale bar = 10 mm. (E–F) Quantification of the %
Ki-67+ pancreatic (E) duct and (F) duct adjacent cells in mice treated with control Ig or Fc-TWEAK twice weekly. Data are shown as mean6SEM (n= 4).
* p,0.05 for Fc-TWEAK vs control Ig treatment. (G–H) Quantification of the % Ki-67+ (G) duct and (H) duct adjacent cells in normal adult WT or Fn14
KO mice treated with control Ig or Fc-TWEAK twice per week. Data are shown as mean6SEM (n= 4) for percentage of Ki-67+ duct cells (E&G) or Ki-67+
duct adjacent cells per total duct cells (F&H); * p,0.05 for Fc-TWEAK treatment vs control Ig.
doi:10.1371/journal.pone.0072132.g002
Figure 3. TWEAK treatment induces Ngn3 expression in pancreatic duct cells. Immunostaining for (A) Ngn3 (yellow), (B) CK (green) and (C)
Ngn3/CK (shown as merge) on day 5 of chronic TWEAK treatment. Scale bar = 10 mm. (D) Quantification of Ngn3+ cells on day 5 after twice weekly
control or TWEAK treatment. Each point represents an individual animal, with horizontal bar the mean of 4 mice/group.
doi:10.1371/journal.pone.0072132.g003
Beta Cell Neogenesis in Adult Mice
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Chronic TWEAK treatment induces focal ductal structures
with characteristics of regenerating foci in normal adult
mice
Given the appearance of Ngn3 expression in normal adult
mouse pancreas at day 5 after Fc-TWEAK treatment, we
investigated the effects of longer term TWEAK treatment. At
day 18 after chronic Fc-TWEAK but not control Ig treatment, we
observed the appearance of focal areas characterized by well-
defined structures of proliferating ductules surrounded by mesen-
chymal cells, with some hormone-expressing cells (insulin+ or
glucagon+) within the duct epithelium as well as scattered
hormone-expressing cells (Figure 4A–4E). Hormone+ cells bud-
ding from proliferating ductules suggest that they may be newly
formed and have not yet migrated to form islets. Consistent with
this notion, some of these insulin+ cells had strong significant pan-
CK immunostaining (Figure S5. No bihormonal insulin+gluca-
gon+ cells were seen.
These focal areas induced by TWEAK treatment are similar to
those transiently found in adult rats after Px, which have been
shown to form new pancreatic lobes [6,8,29,30]. In addition,
concentrated CD3+ or F4/80+ cells were restricted to these
TWEAK-induced focal areas (Figure 4G–4H) and not generalized
throughout the rest of the pancreas (Figure S3) at day 18 after
chronic treatment, much as in the focal regions of regeneration
after Px but not the remnant pancreas (Figure S6). For each
animal, we examined over 10 full footprint pancreatic sections ($
200 mm apart) representing the entire pancreatic block. The
incidence of ductal structures with characteristics of regenerating
foci was low, with generally only one large area per pancreatic
section from each Fc-TWEAK-treated mouse; no such foci were
found in sections from control-Ig treated mice.
Notably, Fn14 protein expression was difficult to detect in
untreated mice (data not shown) but readily detectable in the
ductal structures in these focal areas (Figure 4J) and more strongly
expressed than in ducts outside these areas. Thus our data suggest
that the observed areas of ductal structures with characteristics of
regenerating foci originated from pancreatic duct epithelial cells
that were induced by TWEAK to proliferate and expand.
TWEAK induces pancreatic b-cells from duct epithelium
To identify the progeny of TWEAK-induced proliferating duct
cells, we used the CAII-CreERTM:R26R-eYFP (bigenic) mice for
lineage tracing. In the TM-treated bigenic mice, YFP-marked
insulin+ cells were found in 21% of islets and 3.9% aggregates
after chronic Fc-TWEAK treatment but only in 1.2% aggregates
after control Ig treatment (Figure 5A and Table 1). Of interest, the
labeled cells were most often seen as a few cells within islets
(Figure 5B). As an additional control to rule out possible induction
of CAII by TWEAK, MIN6 cells were treated for 24 and 48 hrs
with TWEAK. QPCR analysis showed that TWEAK did not
induce an increase of the extremely low level of CAII mRNA
expressed in this murine insulin expressing cell line (Figure S7).
Fn14 deficiency delays pancreatic regeneration after Px
Since our studies have shown that TWEAK overexpression
induces pancreatic b-cell neogenesis in normal adult mice, we
asked whether the endogenous TWEAK/Fn14 pathway plays a
role in pancreatic regeneration. Fn14 is dramatically increased in
injured and diseased tissues [15], so we investigated whether Fn14
expression was upregulated in the Px model. Previously we defined
three stages of regenerating foci after Px [8]: young, intermediate,
and mature stage foci, as illustrated in Figure 6E with CK staining.
Figure 4. Chronic TWEAK treatment mimics the response to the partial pancreatectomy. Ductal structures with characteristics of
regenerative foci were identified by H&E staining (A) at day 18 after TWEAK treatment twice weekly in all 4 treated animals. Inset of (A) is shown on
serial sections stained with Ki-67 (B), CK (C), insulin (D) and glucagon (E). (F–H) Serial sections of area from another representative animal were stained
with H&E (F), CD3 (G) F4/80 (H); isotype control (I) and Fn14 (J). The islets were labeled as ‘‘i’’. Scale bar = 50 mm in all panels.
doi:10.1371/journal.pone.0072132.g004
Beta Cell Neogenesis in Adult Mice
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Fn14 was clearly expressed at relatively high levels in the
proliferating ductules of immature regenerating focal areas 4 days
after Px but not in mature regenerating focal areas in which there
were already differentiated acinar and islet cells (Figure 6A–6D).
Pancreatic regeneration was compared between WT and Fn14
KO mice by assessment of the number of regenerating foci, total
area of the foci and their maturity at several time points after
surgery. WT mice exhibited increased number and total area of
foci on day 4, which declined by day 7. In contrast, Fn14 KO mice
had different kinetics and extent of regeneration, with a delay in
increased number and decreased area of foci of regeneration
compared to WT (Figure 6F–6G). Thus Fn14 deficiency both
delayed the initiation of foci formation (as seen by the decreased
number of foci at 4 days in Fn14 KO compared to WT mice) and
limited their expansion (as seen by the smaller total area of foci). A
difference in WT vs KO mice was also observed in foci
maturation. At 4 days post surgery, WT mice had a greater
proportion of mature foci than young foci. Yet by day 7, the
distribution has shifted in favor of young foci, presumably because
the mature foci reached a stage at which they are no longer
Figure 5. TWEAK promotes pancreatic regeneration through activation of pancreatic duct-derived progenitor cells. (A) CAII-
CreERTM:R26R-eYFP (bigenic) mice were implanted with 3-week slow-release TM pellets at 4 weeks of age, followed by a 1 week washout period, and
received treatment at 8 weeks of age twice weekly for 2 weeks, and killed at 18 days after start of treatment. (B) In sections from TM-treated mice
immunostained for YFP (green) and insulin (red), YFP-marked insulin+ (coexpression, yellow) cells could be found in small aggregates and within
islets. In control bigenic animals without tamoxifen, control Ig or Fc-TWEAK treatment, no labeled cells were found. Scale bar = 50 mm in left two
panels and 20 mm in far right panel. Quantification of labeled islets and aggregates is presented in Table 1.
doi:10.1371/journal.pone.0072132.g005
Table 1. Quantification of YFP marked insulin+ cells in CAII-CreERTM:R26R-eYFP (bigenic) mice 18 days after chronic Fc-TWEAK or
control Ig treatment.
Treatment
group
N
(animals)
# of YFP+
islets
/animal (%)
Total islet #
counted/
animal
# of YFP+
aggregates/
animal (%)
Total
aggregate #/
animal
YFP+ cells
in islets/
animal
YFP+ cells
in aggregates/
animal
Control (no TM &
drug treatment)
5 0 41.069.4 0 67.6610.5 0,0,0,0,0 0,0,0,0,0
TM + control
Ig
6 0 4565.8 1.060.3 (1.2) 81.3614.9 0,0,0,0,0,0 1, 0, 2, 1, 1, 4
TM + Fc-
TWEAK
5 1065.4 (21) 4765.0 2.261.3 (3.9) 56.064.6 4, 14, 9, 194,
18
0,3,1,19,0
All animals were bigenic CAII-CreERTM:R26-eYFP mice. Control mice had no TM or drug (control Ig or Fc-TWEAK) treatment. For each animal, all insulin positive cells on a
single full footprint pancreatic section were examined for co-expression with eYFP in islets or in aggregates (defined as being 8 cells or less in cross section). Mean
values 6SEM are reported, and the last two columns report individual values/animal.
doi:10.1371/journal.pone.0072132.t001
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distinguishable from remnant tissue and therefore not counted. In
contrast Fn14 KO mice at day 4 had a greater proportion of
younger stage regenerating foci (Figure 6H) and even by day 7
post surgery, their maturation still lagged behind that of WT, with
a higher proportion of intermediate foci and a trend to more
mature stage foci (Figure 6I). Taken together, these data indicate
that disruption of Fn14 signaling delays initiation of formation of
regenerating foci and limits their expansion as compared with WT
mice.
Proposed model (Figure 7)
In this study, we demonstrated that in normal adult pancreas, in
vivo TWEAK treatment promotes duct cell proliferation, induces
Ngn3 expression and focal duct structures with characteristics of
regenerating foci. The cell precursor/progeny relationship was
addressed by lineage tracing, proving that duct epithelial cell
progenitors give rise to pancreatic b cells in response to TWEAK.
Furthermore, we demonstrated a role for endogenous TWEAK in
promoting pancreatic regeneration after Px.
Discussion
In this report, we identify TWEAK as a novel pancreatic b-cell
neogenesis factor, demonstrating that it promotes b-cell formation
from pancreatic duct epithelium in normal adult mice. Impor-
tantly, we also show that the endogenous TWEAK/Fn14 pathway
plays an important role in regulating pancreatic regeneration in
the Px model.
Studies have shown various sources of new pancreatic b-cells in
different models of injury [9,10,11,12]. While there is some
controversy, multiple reports support that pancreatic duct cells
have progenitor potential that is activated after injury [1,6,7,8,10],
recapitulating their role in embryonic development [31]. Molec-
Figure 6. Fn14 is transiently expressed in the regenerating foci after Px and its deficiency delays pancreatic regeneration. (A–D)
Representative images from serial sections immunostained for Fn14 (green) (A, C) and CK (red)/insulin (green)/DAPI (blue) (B, D) show transiently
enhanced expression of Fn14 in immature regenerating foci (A, B) but not in mature foci (C, D). E. Representative stages of the maturation of the
regenerating foci as previously defined [11]. (F–G) Quantification of (F) total foci number and (G) total foci area per section of Fn14 KO mice or WT
mice at day 4 and day 7 post surgery. (H–I) Distribution of foci at different stages of differentiation in Fn14KO and WT mice at (H) day 4 or (I) day 7
post surgery. Number and stage of regenerating foci were assessed on at least two sections/animal ($ 200 mm apart) in WT and Fn14 KO mice (n$ 5
per group). No regenerating foci were identified in sham-operated mice. Data are shown as mean6SEM; * P,0.05 for Fn14 KO vs WT mice.
doi:10.1371/journal.pone.0072132.g006
Beta Cell Neogenesis in Adult Mice
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ular pathways regulating this process have been identified through
KO mice [25,32], and several pharmacological approaches have
been pursued for b-cell regeneration, including GLP-1 receptor
agonists [33,34], gastrin [35,36], growth factors including TGFa
[37], KGF [38], betacellulin [39], islet neogenesis-associated
protein (INGAP) [40], and the cytokine IFNc [7]. However, none
of these studies proved by lineage tracing the cell of origin of de
novo-generated b cells. Our studies contribute new findings, that
TWEAK acts as a novel pancreatic b-cell neogenesis factor
through activation of ductal epithelial progenitor cells in normal
adult mice.
The neogeneic effect of TWEAK is initially manifested by the
proliferation of duct epithelial cells, consistent with its capacity as a
mitogenic factor for the progenitorss in other tissues [15]. We also
observed proliferating duct adjacent cells, which did not express
duct epithelial marker CK but were still in contact with the duct
epithelium. These duct adjacent cells were not acinar, islet or
inflammatory cells. The kinetics of their proliferation lagged
slightly behind that of the ductal epithelial cells suggesting the
intriguing possibility that they were delaminated ductal epithelial
cells migrating away from the duct; however we cannot rule out
that they are mesenchymal cells. Our observation that the
endocrine progenitor cell marker Ngn3 was expressed by both
the duct and duct adjacent cells also supports that these cells have
islet progenitor cell potential. While the fate of these Ngn3+ cells
was not formally addressed in our study, we definitively prove that
the duct epithelial cells were the progenitors of b-cells after chronic
TWEAK treatment based on the appearance of YFP+/insulin+
cells in a ductal epithelium lineage tracing system. Interestingly,
we found that the labeled cells were most often seen as a few cells
within islets and only occasionally as aggregates. This finding may
appear at odds with our observation of insulin+ cells in the focal
ductal structures shown at the same timing. However, given that
those ductal structures were observed at a low frequency, it is not
surprising that our fate mapping result represents the balance of
the tissue. We speculate that the proliferating labeled duct and
duct adjacent cells migrated and coalesced into islet cell clusters
and pre-existing islets. We found YFP+/glucagon+ cells within
islets, although less frequently than the YFP+/insulin+ cells (data
not shown), presumably reflecting the lower frequency of a-cells as
compared to b-cells. Since the labeling efficiency of this lineage
tracing mouse strain is around 30%, the regenerative effect of
TWEAK may be underestimated in our study. The recent report
that tamoxifen can induce Cre-loxP recombination in pancreatic
islets in adult mice long after administration due to its retention in
the body complicates all lineage tracing experiments using the
Cre-LoxP system. [41]. However, since in our mouse model the
transgene CAII and Cre are expressed in murine ductal but not in
murine islet b-cells [10] and as we showed Tweak does not induce
CAII in b-cells, such retention if it occurred would only label the
ducts.
Our studies show that the regenerative activity of TWEAK in
the adult pancreas is dependent on its receptor Fn14. Our data
suggest that TWEAK may act directly through Fn14 expressed on
duct epithelial cells to induce their proliferation as an early step in
the neogeneic process and is consistent with the lack of
proliferative effect of TWEAK on acinar and islet cells in our
study. Enhanced Fn14 expression was detected on focal duct
structures characterized by extensive proliferation induced after
18 days chronic TWEAK treatment. Fn14 expression was also
increased after Px, consistent with its induced expression after
injury. Notably, the increased Fn14 expression after Px is only
observed transiently in immature foci, not mature foci, again
consistent with an important role early in the process of pancreatic
Figure 7. Proposed Model for TWEAK’s effect on pancreatic regeneration. TWEAK signals through Fn14, which is normally expressed at low
levels in adult pancreatic ducts and upregulated after injury, resulting in proliferation of duct epithelium followed by differentiation to mature
pancreatic cell types, including b-cells. In addition, TWEAK/Fn14 signaling induces a localized leukocyte infiltrate that may be beneficial to the tissue
regeneration, thereby creating a positive feedback loop. Although not addressed in the current study, this likely occurs through induction of
chemokines or cytokines that promote inflammatory cell recruitment. We speculate that the proliferating duct epithelial cells regress to a less
differentiated state with progenitor potential, giving rise to Ngn3+ endocrine progenitors that then differentiate to new endocrine cells.
doi:10.1371/journal.pone.0072132.g007
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regeneration. In human pancreas, various levels of Fn14 protein
were observed. As in normal adult mice, several human donors
showed only faint Fn14 immunostaining. Interestingly, relatively
high Fn14 expression was observed on duct cells that were
prominent in the pancreas of a young, obese donor, suggesting
that it may be induced as a compensatory mechanism in this
condition. Although we detect Fn14 expression in human islets,
this could not be addressed in mice since their islets had no
apparent Fn14 expression; this will be a point of future study.
Regenerating foci have been observed after Px [3,6,8,29] and in
other models of b-cell regeneration, including PDL [42],
transgenic mice overexpressing interferon c (IFN-c) on the human
insulin promoter [7], rats with prolonged glucose infusion [43] and
spontaneous autoimmune BB-rats [44]. They are well-defined
structures consisting of abundant fibroblast-like stromal cells,
increasingly branched ductules, and eventually acinar and islet
cells that form new lobes of pancreas indistinguishable from the
original pancreatic tissue. After Px, proliferation of cells within the
common pancreatic duct [6,8] is followed by their de-differenti-
ation/expansion and the transient appearance of regeneration
foci. Importantly, we demonstrated that overexpression of a single
factor, TWEAK, can induce the appearance of similar structures
as those in the response to Px.
We also demonstrated for the first time that the endogenous
TWEAK/Fn14 pathway can regulate pancreatic regeneration.
Fn14 deficiency delayed pancreatic regeneration after Px, with
similar results obtained in the TWEAK KO mouse (data not
shown). The mechanism of action of TWEAK/Fn14 is early in the
regeneration process, with delayed initiation and limited expan-
sion of the regeneration foci in the KO mice. The delay in foci
maturation is most likely secondary to the delays in these early
events.
Specialized phagocytes also play an important role in tissue
development and regeneration [45]. Macrophages are important
in fetal pancreatic development, especially for ductal branching
[46], as are phagocytes in regenerative responses to tissue injury in
other organs [18] and [47]. Regenerating foci after Px and similar
focal structures induced by chronic TWEAK administration in
normal adult mice also contain local immune infiltrates, especially
F4/80+ macrophages, but notably, chronic TWEAK treatment
did not induce generalized inflammation. As the function of the
local infiltrates was not directly addressed, we cannot rule out their
contribution to pancreatic regeneration, possibly by release of
cytokines and interaction with other non-inflammatory cells in the
immediate vicinity.
In conclusion, our study sheds new light on the regulation of
pancreatic b-cell regeneration with identification of TWEAK/
Fn14 as a novel pathway promoting neogenesis in normal adult
animals from pancreatic ductal epithelium. Furthermore, we
identify TWEAK overexpression as a valuable tool to elucidate
molecular and cellular pathways of b-cell regeneration and as a
potential means to pharmacologically promote pancreatic b-cell
regeneration for diabetes treatment.
Supporting Information
Figure S1 Acute TWEAK treatment promotes proliferation of
duct and duct adjacent cells. Quantification of the % Ki-67+ duct
(A) and duct adjacent cells (B) per total duct cells in pancreas from
normal adult mice at various time points after single injection of
TWEAK injected on day 0. Data are shown as mean6SEM
(n=4); * P,0.05 for TWEAK treatment vs control.
(TIFF)
Figure S2 TWEAK treatment does not induce apoptosis in
pancreas. Sections of pancreas from mice treated twice per week
with control (A) or TWEAK (B) were assayed for TUNEL signal
and no increase was seen at any of the time points, examined day
1, 3, 4, 5, 10 and 18; representative sections shown from day 18
after treatment. (C) Lymph node as a positive control of TUNEL
staining. Scale bar = 100 mm.
(TIFF)
Figure S3 TWEAK treatment does not induce generalized
pancreatic inflammation. Serial sections of pancreas from normal
adult mice treated twice weekly with control (A, D) or TWEAK (B,
E) immunostained for CD3 (A, B) and F4/80 (D, E) on day 18
after treatment. Positive control staining in spleen for CD3
staining (C) and in liver for F4/80 staining (F). Scale bar = 50 mm.
(TIFF)
Figure S4 TWEAK-induced duct cell proliferation does not
involve Fc-effector function nor is caused by peritonitis. (A–B)
Quantification of % Ki-67+ duct (A) and duct adjacent cells (B) per
total duct cells in pancreas from normal adult mice at day 5 after
Ctrl mIgG2a (P1.17, control for Fc-TWEAK), Fc-TWEAK, Ctrl
mIgG1 (1E6, (control for Agly-Fc-TWEAK) or Agly-Fc-TWEAK
twice weekly. Controls (white bars); TWEAK treated (black bars).
(C–D) Quantification of the % Ki-67+ duct (C) and duct adjacent
cells (D) per total duct cells in pancreas at day 5 after Crtl (control
Ig P1.17) or Fc-TWEAK subcutaneously (s.c.) or intraperitoneally
(i.p.). Controls (white bars); TWEAK treated (black bars). Data are
shown as mean6SEM (n= 4); * P,0.05 for TWEAK treatment vs
control.
(TIFF)
Figure S5 Co-expression of insulin and pan-cytokeratin in some
cells of the focal ductal structures after chronic TWEAK
treatment. Immunofluorescent staining of pancreas at day 18
after chronic TWEAK treatment (A) shows some insulin positive
cells (red) also express panCK (green) (coexpression- yellow/
orange) in the complex ductal structures but the Ig controls (B) do
not have these regions and have no co-expression of the insulin
and panCK. Magnification bar = 50 mm.
(TIFF)
Figure S6 Inflammatory infiltrates were recruited to the
regenerating foci after Px. Serial sections from sham-operated
(A, B) and Px at 4 days post surgery (C, D) were immunostained
for CD3 (A, C) and F4/80 (B, D). Scale bar = 200 mm.
(TIFF)
Figure S7 Culture of MIN6 cells with TWEAK does not induce
CAII mRNA. Q-PCR of MIN6 cells treated for 24 or 48 hr with
Tweak (100 ng/ml). Data were normalized to ribosomal S18 and
expressed relative to time zero. Data are shown as mean6SEM
from 4 independent experiments.
(TIFF)
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